Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.4M 2.25M 2.05M 3.85M 265M 3.91M 26.37M 10.31M 133M 10.41M 10.19M 441M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.57M 8.06M 7.33M 13.77M 949M 14M 94.4M 36.91M 475M 37.27M 36.46M 1.58B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.35%+1.95%+52.76%+205.60% 29.3B
Weighted average by Cap. -1.09%+0.55%+50.23%+164.99%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.99 0.1 0.7 0.27 3.5 0.27 0.27 11.63 0.14 0.12 0.11 0.1 0.19 12.94 0.19 1.29 0.5 6.48 0.51 0.5 21.54
Net income -3.1M -2.68M -2.52M -2.29M -4.31M -297M -4.38M -29.53M -11.54M -149M -11.66M -11.4M -494M -18.47M -15.96M -14.99M -13.64M -25.64M -1.77B -26.06M -176M -68.69M -885M -69.36M -67.86M -2.94B
Net Debt 7.1M 6.13M 5.76M 5.24M 9.85M 678M 10.01M 67.47M 26.38M 340M 26.64M 26.06M 1.13B 7.15M 6.18M 5.81M 5.28M 9.93M 684M 10.09M 68.02M 26.6M 343M 26.86M 26.27M 1.14B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-